16:44 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

AZ's Farxiga plus Onglyza non-inferior to Lantus in Phase IIIb for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Farxiga (Forxiga) dapagliflozin plus Onglyza saxagliptin met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 24 in a Phase IIIb trial to...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
16:50 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Mylan, Biocon get CRL for insulin glargine follow-on

Mylan N.V. (NASDAQ:MYL) and partner Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said they recently received a complete response letter from FDA for their follow-on of diabetes drug Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY). The partners said they...
23:08 , Jun 5, 2018 |  BC Extra  |  Company News

Mylan, Biocon get CRL for insulin glargine follow-on

Mylan N.V. (NASDAQ:MYL) and partner Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said they recently received a complete response letter from FDA for their follow-on of diabetes drug Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY). The partners said...
00:46 , Apr 28, 2018 |  BioCentury  |  Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed, former...
19:07 , Apr 27, 2018 |  BC Extra  |  Company News

Sanofi's Dupixent misses sales estimates, Regeneron slips

Sanofi (Euronext:SAN; NYSE:SNY) reported 1Q18 earnings, including sales of atopic dermatitis drug Dupixent dupilumab that missed estimates. The company's partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) slid $10.92 to $313.05 on the news Friday, shedding nearly $1.2 billion...
22:15 , Apr 24, 2018 |  BC Extra  |  Company News

Diabetes franchise drives 1Q18 for Lilly

Strong sales from the diabetes franchise of Eli Lilly and Co. (NYSE:LLY) led to 1Q18 results that outpaced consensus estimates. On Tuesday, the pharma reported revenue of $5.7 billion for the period, up 9% from...
17:16 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Mylan, Biocon insulin glargine biosimiliar approved in EU and Australia

Mylan N.V. (NASDAQ:MYL) said the European Commission and Australia's Therapeutic Goods Administration each approved Semglee, a biosimilar of diabetes drug Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY). Mylan co-developed Semglee with Biocon Ltd. (NSE:BIOCON; BSE:BIOCON). The...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
19:47 , Dec 8, 2017 |  BC Extra  |  Financial News

Tasly unit invests $50M in Chinese diabetes play Genova

Genova Biotech Co. Ltd. (Changzhou, China) received a $50 million investment from an undisclosed subsidiary of Tasly Holdings Group Co. Ltd. (Shanghai:600535). According to Genova financial advisor China Renaissance, the investment is part of Genova’s...